title: The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study.
abstract: BACKGROUND
  Increased demand for oral anticoagulation has resulted in wider adoption of computer-assisted dosing in anticoagulant clinics. An economic evaluation has been performed to investigate the cost-effectiveness of computer-assisted dosing in comparison with manual dosing in patients on oral anticoagulant therapy.
  
  
  METHODS
  A trial-based cost-effectiveness analysis was conducted as part of the EAA randomized study of computer-assisted dosage vs. manual dosing. The 4.5-year multinational trial was conducted in 32 centres with 13 219 anticoagulation patients randomized to manual or computer-assisted dosage. The main outcome measures were total health care costs, clinical event rates and cost-saving per clinical event prevented by computer dosing compared with manual dosing.
  
  
  RESULTS
  Mean dosing costs per patient were lower (difference: euro47) for computer-assisted dosing, but with little difference in clinical event costs. Total overall costs were euro51 lower in the computer-assisted dosing arm. There were a larger number of clinical events in the manual dosing arm. The overall difference between trial arms was not significant (difference in clinical events, -0.003; 95% CI, -0.010-0.004) but there was a significant reduction in events with DVT/PE, suggesting computer-assisted dosage with the two study programs (dawn ac or parma 5) was at least as effective clinically as manual dosage. The cost-effectiveness analysis indicated that computer-assisted dosing is less costly than manual dosing.
  
  
  CONCLUSIONS
  Results indicate that computer-assisted dosage with the two programs (dawn ac and parma 5) is cheaper than manual dosage and is at least as effective clinically, indicating that investment in this technology represents value for money.
authors.affiliation: Health Economics, School of Health and Population Sciences, University of Birmingham, Birmingham. s.jowett@bham.ac.uk
authors.forename: S
authors.initials: S
authors.lastname: Jowett
authors.forename: S
authors.initials: S
authors.lastname: Bryan
authors.forename: L
authors.initials: L
authors.lastname: Poller
authors.forename: A M H P
authors.initials: AM
authors.lastname: VAN DEN Besselaar
authors.forename: F J M
authors.initials: FJ
authors.lastname: VAN DER Meer
authors.forename: G
authors.initials: G
authors.lastname: Palareti
authors.forename: C
authors.initials: C
authors.lastname: Shiach
authors.forename: A
authors.initials: A
authors.lastname: Tripodi
authors.forename: M
authors.initials: M
authors.lastname: Keown
authors.forename: S
authors.initials: S
authors.lastname: Ibrahim
authors.forename: G
authors.initials: G
authors.lastname: Lowe
authors.forename: M
authors.initials: M
authors.lastname: Moia
authors.forename: A G
authors.initials: AG
authors.lastname: Turpie
authors.forename: J
authors.initials: J
authors.lastname: Jespersen
mesh_terms: D000284:Administration, Oral; D000465:Algorithms; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000191:economics / Q000628:therapy; D003362:Cost-Benefit Analysis; D005060:Europe; D006801:Humans; D012984:Software; D013678:Technology, Pharmaceutical / Q000379:methods; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000191:economics / Q000628:therapy
chemical_list: D000925:Anticoagulants